Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexapro “approvable” for GAD

Executive Summary

Forest still anticipates early 2004 launch of generalized anxiety disorder indication for Lexapro despite Sept. 26 "approvable" letter from FDA. Supplemental NDA for panic disorder submitted April 30, 2002 not affected by GAD setback, Forest says. The company also plans an early 2004 filing for social anxiety disorder...
Advertisement

Related Content

Forest Lexapro “Re-Launch” For Generalized Anxiety Set For Mid-January
Advertisement
UsernamePublicRestriction

Register

PS042573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel